Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Here's A Better Pick Over Abbott Stock
07:15am, Tuesday, 31'st May 2022
If we look at stock returns, Abbott's -1% return is better than Teva's -13% change over the last twelve months.
Teva, Allergan reach $161.5 million opioid settlement with West Virginia
10:03am, Wednesday, 25'th May 2022
(Reuters) -Teva Pharmaceutical Industries and AbbVie's Allergan unit reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia, state attorne
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
04:08pm, Tuesday, 17'th May 2022 Benzinga
Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities.
The Teva P
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2022
02:21pm, Tuesday, 17'th May 2022 Benzinga
Upgrades
Tudor Pickering upgraded the previous rating for Tesla Inc (NASDAQ:TSLA) from Sell to Hold. In the first quarter, Tesla showed an EPS of $3.22, compared to $0.93 from the year-ago quarter. A
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
01:57pm, Tuesday, 17'th May 2022
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Di
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
12:21pm, Tuesday, 17'th May 2022
Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) stock, according to BofA Securities.
Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague
09:06am, Thursday, 12'th May 2022 The Motley Fool
With the broader market tumbling, value stocks are bound to come into focus.
Stock Market Plunge: 2 Value Stocks to Buy and 1 to Avoid Like the Plague
05:06am, Thursday, 12'th May 2022
With the broader market tumbling, value stocks are bound to come into focus.
Teva's Q1 Results: Is the Stock About to Crash?
08:35pm, Thursday, 05'th May 2022 The Motley Fool
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
Teva's Q1 Results: Is the Stock About to Crash?
04:35pm, Thursday, 05'th May 2022
The company met analyst expectations for revenue and profitability, yet that's not necessarily a good thing.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
03:07pm, Wednesday, 04'th May 2022 Zacks Investment Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022
02:17pm, Wednesday, 04'th May 2022 Benzinga
Upgrades
Craig-Hallum upgraded the previous rating for Pros Holdings Inc (NYSE:PRO) from Hold to Buy. Pros Holdings earned $0.21 in the first quarter, compared to $0.22 in the year-ago quarter. At the
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
12:47pm, Wednesday, 04'th May 2022
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Teva Pharmaceutical Industries (TEVA) Q1 2022 Earnings Call Transcript
03:00pm, Tuesday, 03'rd May 2022 The Motley Fool
TEVA earnings call for the period ending March 31, 2022.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
